Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EPS (Basic) (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of EPS (Basic) readings, the most recent being -$0.47 for Q4 2025.

  • For the quarter ending Q4 2025, EPS (Basic) fell 62.07% year-over-year to -$0.47, compared with a TTM value of $0.17 through Dec 2025, up 110.69%, and an annual FY2025 reading of $0.18, up 111.25% over the prior year.
  • EPS (Basic) hit -$0.47 in Q4 2025 for Apellis Pharmaceuticals, down from $1.71 in the prior quarter.
  • The five-year high for EPS (Basic) was $1.71 in Q3 2025, with the low at -$2.72 in Q2 2021.
  • Median EPS (Basic) over the past 5 years was -$1.1 (2023), compared with a mean of -$1.04.
  • The sharpest move saw EPS (Basic) tumbled 248.54% in 2021, then surged 471.74% in 2025.
  • Year by year, EPS (Basic) stood at -$1.53 in 2021, then increased by 1.96% to -$1.5 in 2022, then soared by 52.0% to -$0.72 in 2023, then skyrocketed by 59.72% to -$0.29 in 2024, then plummeted by 62.07% to -$0.47 in 2025.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.47, $1.71, and -$0.33 for Q4 2025, Q3 2025, and Q2 2025 respectively.